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LAWS AND ETHICS AFFECTING 
CLINICAL TRIALS IN AFRICA 
MARK BARNES & NICK WALLACE 
I. INTRODUCTION 
In recent decades, clinical trials involving human subjects have become in-
creasingly globalized as scientists and medical professionals conduct research in 
developing countries.1  Some of this research seeks to study specific diseases that 
are rare in the United States, such as malaria, dengue fever and tuberculosis. 2  
These studies can help address the lack of treatment options “available for the 
diseases that have the greatest impact in the developing world.”3  Other research 
may be motivated by the opportunity to secure U.S. Food and Drug Administra-
tion (“FDA”) approval of a pharmaceutical product, biological product, or med-
ical device.4 
For industry sponsors, conducting clinical trials abroad offers, in some 
cases, the possibility of significant savings through shorter trial time frames and 
lower costs per participant.  Trials abroad can be completed more rapidly because 
recruiting human subjects in foreign countries has proven substantially easier 
than recruiting volunteers domestically.5  The duration of a clinical trial holds 
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 1. Seth W. Glickman et al., Ethical and Scientific Implications of the Globalization of Clinical Re-
search, 360 NEW ENG. J. MED. 816, 816 (2009) (“Pharmaceutical and device companies have embraced 
globalization as a core component of their business models, especially in the realm of clinical trials.”); 
see, e.g. DANIEL R. LEVINSON, U.S. DEP’T OF HEALTH AND HUMAN SERVICES, OFFICE OF INSPECTOR 
GENERAL, CHALLENGES TO FDA’S ABILITY TO MONITOR AND INSPECT FOREIGN CLINICAL TRIALS i–ii 
(2010) (observing that many clinical trials for FDA-regulated drug products are performed outside the 
United States). 
 2. See REMIGIUS N. NWABUEZE, LEGAL AND ETHICAL REGULATION OF BIOMEDICAL RESEARCH IN 
DEVELOPING COUNTRIES 2–3 (2013); see, e.g., DNDI’S POLICIES, DRUGS FOR NEGLECTED DISEASES 
INITIATIVE, http://www.dndi.org/about-dndi/dndi-policies (last visited Sept. 17, 2016) (stating its mission 
to facilitate ways to promote more research and development for neglected diseases); Finnuala Kelleher, 
The Pharmaceutical Industry’s Responsibility for Protecting Human Subjects of Clinical Trials in Devel-
oping Nations, 38 COLUM. J. L. & SOC. PROBS. 67 (2004) (stating that trial sponsors are attracted to de-
veloping countries for the prevalence of diseases that are rare in the United States).  
 3. What We Do: Discovery & Translational Sciences Strategy Overview, BILL & MELINDA GATES 
FOUNDATION, http://www.gatesfoundation.org/What-We-Do/Global-Health/Discovery-and-Transla-
tional-Sciences (last visited Sept. 17, 2017) (recognizing the need to “advance the goal of creating solu-
tions that can be deployed, accepted, and sustained in the developing world” to help support preventative 
and curative therapies for diseases that are significantly left untreated in developing countries). 
 4. See Glickman et al., supra note 1 (stating that pharmaceutical companies seek to conduct clinical 
trials in developing countries because trials there are more cost-effective and the trials needed for FDA 
new drug approval can be completed more rapidly); see also NWABUEZE, supra note 2, at 4 (noting that 
pharmaceutical companies can bring their new drugs to market “cheaper and faster” by conducting their 
research in developing countries). 
 5. See Yevgenia Shtilman, Pharmaceutical Drug Testing in the Former Soviet Union: Contract 
Research Organizations as Broker-Dealers in an Emerging Testing Ground for America’s Big Pharma, 
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serious financial implications for study sponsors. In 2000, one estimate projected 
that a one-day delay in bringing a major drug to market could result in a loss of 
$1.3 million in unrealized sales for a pharmaceutical company.6  In some cases, 
the overall costs of conducting clinical research abroad are significantly lower 
than the costs of conducting the same research domestically.  Some reports from 
pharmaceutical sponsors suggest that a second-tier center in the United States is 
expected to charge more than ten times what a first-rate academic medical center 
in India charges per case report.7 
Today, significant clinical research supporting FDA applications is con-
ducted abroad.  In 2008, 80 percent of marketing applications approved by the 
FDA for drugs or biologics relied on some data from foreign clinical trials.8  A 
2007 study analyzed the industry-sponsored Phase III trials listed in the Clini-
calTrials.gov registry and found that, for the 20 largest pharmaceutical compa-
nies, approximately one third of the trials were conducted outside of the United 
States and a majority of the study sites were located outside the United States 
(“ex-U.S.” sites).9  As of September 14, 2017, ClinicalTrials.gov showed 47 per-
cent of registered studies as having a “non-U.S. only” location.10  Consequently, 
the legal and ethical implications of clinical trials conducted abroad affect a sig-
nificant number of research participants.  Between October 2007 and September 
2008, trials conducted at 6,500 foreign research sites involved more than 200,000 
subjects.11 
The ethical and legal challenges affecting clinical trials conducted in Africa 
are particularly pronounced, even though African countries host fewer clinical 
trial sites reported to the FDA than many other regions.12  In many developing 
countries, laws, or the lack of enforcement of laws, may offer reduced protections 
 
29 B.C. THIRD WORLD L.J. 425, 432–34 (2009) (describing domestic barriers, such as the lack of volun-
teers and stringent federal regulations, that delay the progression of clinical trials in the United States, 
motivating pharmaceutical companies to seek independent contractors who can help facilitate faster clin-
ical trials in foreign countries with lighter regulatory frameworks). 
 6. See id. at 433. 
 7. See Glickman, supra note 1; see also Shtilman, supra note 5, at 441 (explaining how overseas 
clinical trials gain popularity by costing significantly less than trials in the United States). 
 8. See LEVINSON, supra note 1, at ii. 
 9. See Glickman, supra note 1; see also Shtilman, supra note 5, at 426, 431–32 (noting that both 
the need for large numbers of participants as well as insufficient American volunteers influence the phar-
maceutical companies’ decision to conduct trials abroad). 
 10. See TRENDS, CHARTS, AND MAPS, https://clinicaltrials.gov/ct2/resources/trends (last visited Sept. 
17, 2017). 
 11. LEVINSON, supra note 1, at 11; United States Senate, References, http://www.senate.gov/refer-
ence/glossary_term/fiscal_year.htm (last visited Sept. 17, 2017) (identifying the federal fiscal year as a 
period beginning October 1 and ending September 30).  
 12. See LEVINSON, supra note 1, at 12 (noting that the Office of the Inspector General (“OIG”) ana-
lyzed FDA marketing applications approved in 2008 and found that less than 10 percent of the foreign 
clinical trial subjects and foreign sites were located in the Africa and the Middle East region.  The number 
of clinical trials conducted in Africa and not reported to the FDA is unknown). 
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to human subjects, and local regulatory bodies may lack the capacity to monitor 
clinical trials adequately.13  Clinical trials involving human subjects raise a 
unique set of ethical complications when carried out in developing countries.  
This article lays out the sources of law and ethical principles that apply when 
U.S. academic institutions and corporations sponsor or conduct clinical trials in 
African countries.  Section II of this Article outlines laws that govern research 
conducted in Africa.  In particular, Section II focuses on U.S. statutes and regu-
lations that apply extraterritorially to research conducted abroad and notes cer-
tain gaps in the legal protections afforded to human subjects at ex-U.S. sites.  
Section III of this Article focuses on the specific application of ethical research 
principles to clinical research conducted in Africa, including to research con-
ducted outside the parameters of legal protections for human subjects.  This Sec-
tion briefly outlines the evolution of ethical guidelines governing human subjects 
research and applies principles of ethical conduct to certain paradigms likely to 
emerge when foreign institutions and multi-national companies conduct clinical 
trials in Africa. 
II. LAWS APPLICABLE TO CLINICAL TRIALS CONDUCTED IN AFRICA 
Both foreign and U.S. law may apply when clinical trials are conducted at 
ex-U.S. sites by U.S.-based or U.S.-affiliated entities or researchers.  The non-
U.S. country where the trial site is found may have laws applicable to a range of 
relevant research and non-research activities.  Additionally, certain U.S. statutes 
and regulations apply extraterritorially and regulate conduct at an ex-U.S. clini-
cal research site if the research is funded by the U.S. government or if the data 
from the site are to be submitted to support a U.S. regulatory filing.14  Other U.S. 
laws apply to all activity, regardless of whether U.S. funding or regulatory ap-
proval is involved.15  Not infrequently, U.S. laws regulate a number of aspects 
of ex-U.S. clinical trials, including the site’s protection of human subjects, the 
export of certain materials and data, payments made to officials of foreign gov-
ernments (including medical staff and officials of government-affiliated hospi-
tals), and registration of the ex-U.S. clinical trial.  In addition to identifying cer-
tain research-related activities that are subject to U.S. or other national 
regulation, this Section identifies a category of certain ex-U.S. clinical trials for 
which no country’s human subjects protection law may apply and specifies the 
 
 13. See Glickman, supra note 1, at 818 (noting further that regulatory bodies have limited information 
regarding clinical trials conducted in foreign countries and therefore are unable to serve as effective mon-
itors of the quality of such research). 
 14. See, e.g., 21 C.F.R. § 312.120 (2008). 
 15. See, e.g., William Dubois, Note, New Drug Research, the Extraterritorial Application of the FDA 
Regulations, and the Need for International Cooperation, 36 VAND. J. TRANSNAT’L L. 161, 189–90 
(2003). 
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circumstances in which certain sponsors and investigators have a heightened eth-
ical duty to self-regulate to ensure that their research is conducted in conformity 
with the applicable ethical requirements. 
A.  Laws of the Country in Which the Clinical Trial Site is Located 
Before beginning a program of ex-U.S. clinical trials, research sponsors and 
investigators must be aware of the legal requirements that pertain to their activi-
ties in the jurisdictions in which they conduct or sponsor clinical trials.  Some 
countries in Africa have laws that govern the conduct of clinical trials specifi-
cally, and most have non-research-specific laws affecting the operations of clin-
ical trials.16  For example, a host country may have laws regulating the drugs, 
devices or biotechnology used in the clinical trial; national and local taxation 
laws; labor and wage laws; immigration laws regulating work permits and busi-
ness visas for the site’s expatriate staff; professional licensure laws governing 
the site’s doctors, nurses and pharmacists; privacy laws and data export laws; 
tissue and blood sample export control laws; and intellectual property laws. 
As one example, South Africa has adopted detailed legal requirements for 
the protection of human research subjects and data privacy.17  These require-
ments are not identical to the U.S. human subjects and data privacy protections 
that apply extraterritorially.18  Clinical trials involving human research in South 
Africa must, among other requirements, register the research in the South Afri-
can National Clinical Trials Register, submit the research proposal for ethics re-
view and approval to a health research ethics committee registered in South Af-
rica, and provide detailed information in order to obtain legally adequate 
informed consent.19 
South African law protects the privacy of “personal information,” which is 
broadly defined to include biometric information, medical history, demographic 
information, and contact information.20  Because the law requires the “responsi-
ble party” to “take reasonably practicable steps to ensure that the data subject is 
aware of . . . the fact that . . . the responsible party intends to transfer the infor-
mation to a third country,” many sponsors of clinical trials in South Africa must 
notify the subject of their intent to transfer the data to one or more foreign coun-
tries for further analysis.21  Additionally, if the sponsor intends to submit the data 
 
 16. See, e.g., NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL, NAFDAC 
GOOD CLINICAL PRACTICE GUIDELINES 2016, http://www.nafdac.gov.ng/index.php/guidelines/cliinical-
trials. 
 17. See generally Protection of Personal Information Act 4 of 2013 (S. Afr.) (protecting “personal 
information processed by public and private bodies,” including information of human test subjects). 
 18. See infra Part II.B. 
 19. See Government Notice (GN) R719/2014 (S. Afr.). 
 20. Protection of Personal Information Act 4 of 2013 §1 (S. Afr.). 
 21. Id. at § 18(1)(g). 
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to multiple foreign regulatory agencies to gain approval for marketing a drug, 
device or biologic product, the sponsor will likely wish to de-identify the per-
sonal information contained in the data to avoid the requirement to describe to 
the research subject “the level of protection afforded to the information by” the 
third countries to which the personal information is transferred.22 
Other countries in Africa may, however, lack robust legal regimes to protect 
human research subjects.23  The Office for Human Research Protections 
(“OHRP”) of the U.S. Department of Health and Human Services (“DHHS”) 
maintains an International Compilation of Human Research Standards (“the 
Compilation”).24  The Compilation catalogues more than 1,000 laws, regulations, 
and guidelines governing human subjects research in 126 countries.25  As of the 
2017 edition of the Compilation, OHRP identified only 25 African countries with 
laws specifically governing general human subjects research; research injury; 
clinical trial registries; drugs and devices; human biological materials; genetic 
research; or embryos, stem cells, and cloning.26  Some scholars have noted that 
this absence of regulation may stem from an effort to attract the benefits of clin-
ical research to countries where there is little access to medical research to benefit 
the population.27 
When conducting clinical trials in countries that lack laws specifically gov-
erning human subjects research, research sponsors and investigators may find 
themselves operating entirely outside the familiar legal frameworks in the U.S. 
that protect research subjects.  U.S. laws protecting human subjects do not reach 
some purely private research conducted in other countries, as discussed below in 
Section II.B.  When clinical trial sponsors and investigators operate outside clear 
legal regimes protecting human subjects, they have an ethical and moral duty to 
ensure that their conduct meets the requirements laid out in the guidelines for 
human subjects research, as discussed in Part III. 
 
 22. Id. 
 23. See Benjamin M. Meier, International Protection of Persons Undergoing Medical Experimenta-
tion: Protecting the Right of Informed Consent, 20 BERKELEY J. INT’L L. 513, 532–33 (2002). 
 24. See OFF. FOR HUM. RES. PROTECTIONS, U.S. DEP’T OF HEALTH & HUM. SERV., INT’L 
COMPILATION OF HUM. RES. STANDARDS (2017). 
 25. See id. 
 26. See id. at 2, 157–66 (noting that the twenty-five identified countries with relevant laws are:  Be-
nin, Botswana, Burkina Faso, Cameroon, Côte-d’Ivoire, Democratic Republic of Congo, Ethiopia, Gam-
bia, Ghana, Guinea, Kenya, Liberia, Malawi, Mozambique, Nigeria, Rwanda, Senegal, Sierra Leone, 
South Africa, Sudan, Tanzania, Tunisia, Uganda, Zambia, and Zimbabwe.  Additionally, OHRP notes that 
it has consulted “in-country persons” to review the listings for accuracy and completeness, but the ongoing 
issuance of new standards prevents the Compilation from serving as an “exhaustive source of all current 
applicable laws.”). 
 27. See Meier, supra note 23. 
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B. United States Laws That Apply Extraterritorially 
Some U.S. laws that protect human research subjects apply extraterritori-
ally when the federal government funds or takes regulatory action based on data 
from a foreign clinical trial.28  Other U.S. laws that do not involve the protection 
of human research subjects apply extraterritorially to clinical trials conducted 
outside the U.S. and regulate aspects of those trials, including the transfer of ma-
terials and data, payments to foreign officials, and registration of the trials.  This 
Subsection analyzes the requirements of these laws as well as their applicability 
to various types of clinical trials. 
1. The Common Rule 
The Federal Policy for the Protection of Human Subjects, located at 45 
C.F.R. part 46, applies extraterritorially, governing all research on human sub-
jects that is “conducted, supported, or otherwise subject to regulation by the fed-
eral government outside the United States.”29  The regulations at 45 C.F.R. part 
46 contain four subparts.30  Subpart A, known as the Common Rule, provides 
basic rules governing research involving human subjects.  Additional subparts 
impose further requirements on human subjects research involving pregnant 
women,31 prisoners,32 and children as subjects.33 
Human subjects research that is covered by the Common Rule must be ap-
proved by an institutional review board (“IRB”), which has the authority to re-
quire modifications to be made or to disapprove covered research activities.34  
The Common Rule further requires that all covered research must secure “the 
legally effective informed consent of the subject or the subject’s legally author-
ized representative.”35  Clinical trials in Africa that are covered by the Common 
Rule may face particular challenges in gaining adequate informed consent of re-
search subjects, as discussed below in Subsection III.B.i. 
 
 28. See Jennifer S. Bard, Closing the Gaps in Human Subject Research Law: Regulating Clinical 
Research Conducted Outside of the United States, 21 ANNALS OF HEALTH L. (ASLME SPEC. ED.) 201, 
202–3 (2012). 
 29. 45 C.F.R. § 46.101(a) (2015) (Specifically, the Common Rule applies to the agencies and depart-
ments that that have taken “appropriate administrative action to make the policy applicable to such re-
search.”  Currently, the Common Rule has been “codified in separate regulations by 15 Federal depart-
ments and agencies,” with an additional three departments or agencies complying with the Common Rule, 
though they have not issued the Common Rule in regulations); see e.g., U.S. DEP’T OF HEALTH & HUM. 
SERV., FED. POL’Y FOR THE PROTECTION OF HUM. SUBJECTS (‘COMMON RULE,’) 
http://www.hhs.gov/ohrp/humansubjects/commonrule/. 
 30. See 45 C.F.R. § 46 (2009). 
 31. See 45 C.F.R. §§ 46.201–07 (2009). 
 32. See 45 C.F.R. §§ 46.301–06 (1978). 
 33. See 45 C.F.R. §§ 46.401–09 (1997). 
 34. See 45 C.F.R. § 46.109 (2005). 
 35. 45 C.F.R. § 46.116 (2005). 
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Clinical trials in Africa are governed by the Common Rule’s human sub-
jects protections if the research falls under any of the three regulated categories.36  
Clinical trials that receive National Institutes of Health (“NIH”) or Centers for 
Disease Control and Prevention (“CDC”) funding, for example, are “supported” 
by a federal agency that follows the Common Rule and are subject to its human 
subjects protections.37  Because the NIH and CDC play a significant role in fund-
ing new drug, vaccine and public health research, it is not uncommon for research 
carried out abroad to be subject to the Common Rule’s requirements. 
Clinical trial sponsors or investigators may apply for a discretionary waiver 
of the Common Rule’s extraterritorial applicability.38  When covered research 
takes place in a foreign country where human subjects protections differ from 
the Common Rule, a U.S. department or agency head may approve the substitu-
tion of the foreign procedures in lieu of the Common Rule’s requirements.39  
However, the official may only approve such a substitution if the official deter-
mines that the policies afford protections that are at least equivalent to those pro-
vided in the Common Rule.40  Because some countries in Africa lack legal pro-
tections for human research subjects, this discretionary waiver will only be 
available when clinical trials are conducted in the subset of countries with pro-
tections for human subjects, and then only if the country’s protections are deter-
mined to be at least equivalent to those provided under the Common Rule. 
2. Food & Drug Administration Regulations Governing Human Subjects 
Protections in Trials Seeking Marketing Approval of a Drug, Device or 
Biological Product 
When clinical trials are conducted in Africa in order to generate data sup-
porting a New Drug Application (“NDA”), a Premarket Approval Application 
(“PMA”) for a medical device, or a Biologics License Application (“BLA”), the 
clinical trials must meet requirements imposed by the FDA.41  The FDA must 
approve an application for any new drug, medical device or biologic delivered 
 
 36. See supra note 1. 
 37. See NAT’L INST. OF HEALTH, CLINICAL R. POL’Y, http://osp.od.nih.gov/office-clinical-research-
and-bioethics-policy/clinical-research-policy/research-involving-human-subjects (last visited Sept. 18, 
2017) (noting that the National Institutes of Health, as an agency of the United States Department of 
Health and Human Services follows the Common Rule); see also U.S. DEP’T OF HEALTH AND HUMAN 
SERV., “HUMAN RESEARCH PROTECTIONS” POL’Y (2010), http://www.cdc.gov/od/science/integ-
rity/docs/cdc-policy-human-research-protections.pdf (last visited Sept. 18, 2017) (noting that the Com-
mon Rule is applicable to all research activities of the Centers for Disease Control and Prevention). 
 38. See IRB Common Rule and HIPAA Waiver Approval, RESEARCH DATA ASSISTANCE CENTER, 
http://www.resdac.org/cms-data/request/materials/irb-common-rule-and-hipaa-waiver-approval (last vis-
ited Sept. 18, 2017) (identifying the criteria and procedures for obtaining a waiver). 
 39. See 45 C.F.R. § 46.101(h) (2015).  
 40. See id. 
 41. See 21 C.F.R. § 314.2 (2015) (drugs); 21 C.F.R. § 814.1 (2015) (medical devices); 21 C.F.R. § 
601.2 (2012) (biologics). 
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into interstate commerce in the United States.42  FDA requirements for foreign 
studies conducted to support a PMA are codified separately from the requirement 
for foreign studies conducted to support an NDA or BLA.43  Substantively, how-
ever, the requirements are similar for the three applications. 
The FDA allows applicants to submit as support for an NDA or BLA “a 
well-designed and well-conducted foreign clinical study not conducted under an 
Investigational New Drug Application (“IND”), if the following conditions are 
met: “The study was conducted in accordance with good clinical practice 
(“GCP”) . . . and; FDA is able to validate the data from the study through an 
onsite inspection if the agency deems it necessary.”44 
Under FDA regulations, GCP includes review and approval (or provision 
of a favorable opinion) by an independent ethics committee (“IEC”) and “obtain-
ing and documenting the freely given informed consent of the subject.”45  The 
FDA will only accept a foreign clinical study of a medical device not conducted 
under an Investigational Device Exemption (“IDE”) as support for a PMA if “the 
data are valid” and the research has been conducted “in conformance with the 
‘Declaration of Helsinki’ or the laws and regulations of the country in which the 
research is conducted, whichever accords greater protection to human sub-
jects.”46  
Foreign clinical trials generating data to support an NDA or BLA are sub-
ject to requirements to obtain approval by a review board and to obtain a sub-
ject’s informed consent under the FDA regulations.47  Likewise, the Declaration 
of Helsinki, which contains the minimum requirements that a study must meet to 
be considered as support for a PMA, requires the submission of the research pro-
tocol to a “research ethics committee.”48  Additionally, the Declaration requires 
 
 42. See id. 
 43. See supra note 1. 
 44. 21 C.F.R. § 312.120(a)(i)–(ii) (2015). Under this section, GCP is defined as a “standard for the 
design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials in 
a way that provides assurance that the data and reported results are credible and accurate and that the 
rights, safety, and well-being of trial subjects are protected.”  It includes review by an independent board 
and obtaining subjects’ informed consent; see also 21 C.F.R. § 312.120(b) (2015) (describing supporting 
information that the FDA requires of an NDA applicant submitting data from a foreign clinical study not 
conducted under an IND). 
 45. 21 C.F.R. § 312.120(a)(i) (2015); see also 21 C.F.R. § 50.20 (2015) (applying the informed con-
sent requirement to foreign clinical trials involving human subjects used to generate data for FDA appli-
cations). 
 46. 21 C.F.R. § 814.15(b) (2015). 
 47. See supra note 1. 
 48. See World Medical Association, Inc., WMA Declaration of Helsinki: Ethical Principles for Med-
ical Research Involving Human Subjects, 59 WORLD MED. J. 199, 200 (2013)(The Declaration explains 
that a “research protocol must be submitted for consideration, comment, guidance, and approval to the 
concerned research ethics committee before the study”; such a committee must be “independent,” “trans-
parent,” “qualified,” and free from any “undue influence” on behalf of the researcher). 
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that investigators obtain the informed consent of human subjects.49  The particu-
lar challenges involved in obtaining informed consent of subjects in clinical trials 
conducted in Africa are discussed below in Subsection III.B.i. 
4. Privacy and Confidentiality Regulations 
The Health Insurance Portability and Accountability Act of 1996 and the 
regulations adopted thereunder (collectively, “HIPAA”) impose confidentiality 
requirements on protected health information (“PHI”) held by a “covered en-
tity.”50  Covered entities include (1) a health plan, (2) a health care clearinghouse, 
and (3) a health care provider, if that entity or person transmits any health infor-
mation in electronic form in connection with a transaction covered by the sub-
chapter.51  PHI is defined as “individually identifiable health information” that is 
transmitted by or maintained in electronic media or in any other form or me-
dium.52 
Avoiding potential extraterritorial application of HIPAA has influenced the 
administration of international clinical trials.  Some sponsors have faced concern 
that HIPAA might apply to the conduct of HIPAA-covered entities when they 
gather PHI abroad.53  The HHS Secretary’s Advisory Committee on Human Re-
search Protections (“SACHRP”) notes that some clinical research sponsors have 
“determined that these concerns can be eased by no longer relying on Covered 
Entities (such as academic research institutions or universities) to assist in the 
coordination of multi-national clinical trials.”54  To reverse any regulatory bias 
against covered entities that could play a valuable role as investigators on foreign 
clinical trials, SACHRP recommends that “the Department give clear guidance 
in the near future on the scope of HIPAA’s application in the international con-
text” and that the guidance restrict the extraterritorial application of HIPAA in-
sofar as possible.55  However, because the Department has not yet issued this 
guidance, commercial sponsors of clinical trials in Africa can, and often do, 
choose to directly contract with local, ex-U.S. hospitals and clinics to conduct 
trials, bypassing covered entity medical centers in the U.S. that, before HIPAA, 
might have acted as the data coordinating center or as the lead clinical trial site.  
Sponsors also often choose to rely on Contract Research Organizations or other 
 
 49. See id. at 200–01. 
 50. See 45 C.F.R. § 164.508(a) (2015). 
 51. See 45 C.F.R. § 160.102(a) (2015). 
 52. 45 C.F.R. § 160.103 (2015). 
 53. See Secretary’s Advisory Committee on Human Research Protections:  Appendix H, U.S. DEP’T 
OF HEALTH & HUM. SERV. OFF. FOR HUM. RES. PROTECTIONS, http://archive.hhs.gov/ohrp/sachrp/appen-
dixh.html (last updated Feb. 9, 2005). 
 54. Id. 
 55. Id. 
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entities that are not HIPAA covered entities when initiating clinical trials in Af-
rica. 
It should be noted that HIPAA is not the only source of a confidentiality 
requirement that applies extraterritorially.  Even when HIPAA does not apply to 
foreign clinical trials, the Common Rule requires that an IRB consider whether 
the research plan includes adequate provisions to protect the privacy of subjects 
and to maintain the confidentiality of the data.56  Therefore, a clinical trial con-
ducted at one or more sites in Africa that is not subject to HIPAA may still be 
subject to privacy and confidentiality requirements imposed through an IRB, if 
the clinical research is subject to FDA human subjects regulations.57  As dis-
cussed above in Subsection II.B.ii, pharmaceutical clinical trials that generate 
research used to support a drug application to the FDA are subject to FDA regu-
lations protecting human subjects, and therefore are already likely to face the 
imposition of confidentiality requirements on clinical trials conducted in Africa. 
5. Export & Import Control Regulations 
When U.S. entities conduct clinical trials in Africa, certain export control 
regulations may restrict their ability to convey some materials and technology 
outside the United States.  The International Traffic in Arms Regulations 
(“ITAR”)58 and Export Administration Regulations (“EAR”)59 apply to all ex-
ports in clinical trials, regardless of whether the federal government has a role in 
funding or receiving data from the trials. 
ITAR’s United States Munitions List designates the “articles, services, and 
related technical data” that are subject to controls as defense articles and services 
under the Arms Export Control Act.60  The Munitions List designates numerous 
toxicological agents, including chemical agents, biological agents, and associ-
ated equipment, as defense articles.61  In order to export any of these agents and 
associated equipment for use in clinical trials, the sponsor must obtain the requi-
site licenses under ITAR.62 
 
 56. See 45 U.S.C. § 46.111(a)(7) (2016). 
 57. See 45 C.F.R. § 46.101 (2016) (applying the privacy and confidentiality requirements of 45 
C.F.R. § 46.111(a)(7) “to all research involving human subjects conducted, supported or otherwise subject 
to regulation by any federal department or agency which takes appropriate administrative action to make 
the policy applicable to such research,” which includes the FDA). 
 58. See 22 C.F.R. § 120 et seq. (2015). 
 59. See 15 C.F.R. § 730 et seq. (2016). 
 60. See 22 C.F.R. § 121.1(a) (2015). 
 61. See 22 C.F.R. § 121.1 (2016) (Category XIV—Toxicological Agents, Including Chemical 
Agents, Biological Agents, and Associated Equipment); see also 22 C.F.R. § 120 et seq. (2016). 
 62. See 22 C.F.R. § 123.1 (2016) (requiring that “any person who intends to export or import tempo-
rarily a defense article must obtain the approval of the Directorate of Defense Trade Controls prior to the 
export or temporary import, unless the export or temporary import qualifies for an exemption under the 
provisions of this subchapter.”). 
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No African countries appear on the current list of countries to which the 
United States categorically refuses to grant a license for the export of defense 
articles and services.63  However, the United States generally also will refuse to 
issue an export license under ITAR for exports to certain nations, such as when 
a United Nations embargo applies to a nation and a potential export is also con-
tained on the Munitions List.64  As of September 2017, countries in Africa sub-
ject to a policy of denials for the export of defense articles and services, except 
when a license may be issued on a case-by-case basis, include the Central African 
Republic, the Democratic Republic of Congo, Eritrea, Libya, Somalia, Sudan, 
and Zimbabwe.65 
The EAR regulates “‘dual-use’ item[s] . . . [having] civil applications as 
well as terrorism and military or weapons of mass destruction (WMD)-related 
applications.”66  Relevant facts for determining the applicability of the EAR ex-
port prohibitions include the listing of an item on the Commerce Control List, 
the identity of a destination country, and the end-use.67  Because the Commerce 
Control List contains various biological and chemical agents that have dual uses, 
those conducting clinical trials in Africa must ensure that exports of materials for 
use in their clinical trials are not prohibited under the EAR. 
6. Foreign Corrupt Practices Act 
Entities that operate in the U.S. must comply with the Foreign Corrupt Prac-
tices Act of 1977 (“FCPA”) when sponsoring or conducting clinical trials outside 
of the U.S.68  The FCPA makes it unlawful for any person to offer, promise or 
pay “any money. . . [or] anything of value” to certain foreign persons in order to 
influence official acts or obtain business.69 
FCPA risks are especially relevant to sponsors and investigators of ex-U.S. 
clinical trials, as the former Assistant Attorney General for the Criminal Division 
of Department of Justice has noted a “significant risk” of FCPA violations in the 
 
 63. See 22 C.F.R. § 126.1(a), (c)(2)–(3) (1993). 
 64. See 22 C.F.R. § 126.1(c) (1993). 
 65. See 22 C.F.R. § 126.1(d)(2) (1993). 
 66. 15 C.F.R. § 730.3 (2013). 
 67. See 15 C.F.R. § 736.2(a) (1996). 
 68. See generally 15 U.S.C. § 78dd-1 (2010). 
 69. 15 U.S.C. § 78dd-1(a)(1)–(3) (2010) (individuals to whom such offers, promises or payments 
may not be made include: 1) “any foreign official for purposes of influencing any act or decision of such 
foreign official in his official capacity,” 2) “any foreign political party or official thereof or any candidate 
for foreign political office for purposes of—influencing any act or decision of such party, official, or 
candidate in its or his official capacity” in order to assist in “obtaining or retaining business for or with, 
or directing business to, any person,” and 3) any intermediary with the knowledge that “all or a portion of 
such money or thing of value will be offered, given, or promised, directly or indirectly, to any foreign 
official, to any foreign political party or official thereof, or to any candidate for foreign political office” 
for the prohibited purposes). 
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field.70  In a 2009 speech, Assistant Attorney General Lanny Breuer stated that, 
“[i]n some foreign countries and under certain circumstances, nearly every as-
pect of the approval, manufacture, import, export, pricing, sale and marketing of 
a drug product may involve a ‘foreign official’” as defined in the FCPA.71 
In Africa, sponsors of clinical trials, CROs and American lead investigators 
conducting a clinical trial may confront a number of scenarios that could give 
rise to FCPA liability as a result of having conferred “any money . . . [or] any-
thing of value” to a foreign official in order to influence official acts or obtain 
business.72  While making an impermissible direct payment to a government of-
ficial to approve an increased study enrollment, for example, would clearly vio-
late the statute, possible liability may attach to many other activities surrounding 
a trial that are not so unambiguously prohibited.  In many countries, hospitals 
hosting clinical trials are most often government-owned or government-con-
trolled, and physicians and other staff administering a clinical trial are govern-
ment or parastatal employees.73  As government or parastatal employees, these 
medical professionals are regarded as “foreign officials” under the FCPA.74 
Payments to government officials (including physician-investigators) who 
are administering or conducting a trial do not become an impermissible payment 
made “to influence official acts or obtain business” if the payments are used to 
fund the trial and are calibrated to fair market value for the services performed.75  
However, the payments must not be intended to gain local regulatory approval 
to conduct the trial or to influence the exercise of any government official’s true 
discretionary authority.76  Monetary payments are not the only transfers to for-
eign government employees that may implicate the FCPA.  Authorship on pa-
pers, for example, when undeserved under applicable academic criteria, may be 
a thing “of value” under the FCPA, because authorship conveys professional 
 
 70. See Gardiner Harris & Natasha Singer, U.S. Inquiry of Drug Makers is Widened, N.Y. TIMES, 
Aug. 13, 2010, http://www.nytimes.com/2010/08/14/health/policy/14drug.html?_r=1. 
 71. Id. (further noting that the depth of involvement of foreign governments and officials in foreign 
health systems, and the competitive nature of the industry, creates risk for illegal payments that could 
corrupt the process of drug development, manufacture, import, export, and pricing). 
 72. 15 U.S.C. § 78dd-1(a)(3) (2010). 
 73. See B. Hanifin, M. Barnes, & N. Berg, Corruption Risks in International Clinical Trials: Navi-
gating Between Anti-Bribery Laws and Local Circumstances, BLOOMBERG BNA MEDICAL RES. L. & 
POL’Y REPORT 1 (Jan. 6, 2016), https://www.ropesgray.com/newsroom/news/2016/01/In-Bloomberg-
BNA-Medical-Research-Law-Policy-Report-Litigators-Review-Corruption-Risks.aspx.  
 74. See 15 U.S.C. § 78dd-1(f)(1)(a) (2010) (defining “foreign official” as “any officer or employee 
of a foreign government or any department, agency, or instrumentality thereof, or of a public international 
organization, or any person acting in an official capacity for or on behalf of any such government or 
department, agency, or instrumentality, or for or on behalf of any such public international organization.”). 
 75. See generally, 15 U.S.C. § 78dd-1 (2010) (providing an exception for payment(s) to foreign gov-
ernments and officials for “routine governmental action” The fair market value of payments tends to sup-
port that bona fide services were purchased). 
 76. See id. (providing that any payment to a foreign government official is impermissible if the pay-
ment is for purposes of influencing the foreign official in his or her official capacity).  
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prestige and career opportunities.  Therefore, in the allocation of any benefit, 
monetary or otherwise, clinical trial sponsors, CROs and lead investigators 
should assure that any benefits or payments are justifiable under FCPA stand-
ards. 
In addition to the FCPA, multinational entities conducting clinical trials in 
Africa must also comply with the United Kingdom Bribery Act if they “carr[y] 
on a business, or part of a business, in any part of the United Kingdom.”77  The 
scope of the United Kingdom Bribery Act extends to U.S.-based research spon-
sors that carry out research in Africa if they, for example, are registered to do 
business in the United Kingdom or sell pharmaceutical, medical device, or bio-
logical products there.  Liability is triggered when a person “associated” with the 
covered commercial entity “bribes another person intending to obtain or retain 
business for [the entity] or to obtain or retain an advantage in the conduct of 
business for [the entity]” and the entity lacks “adequate procedures designed to 
prevent persons associated with [it] from undertaking such conduct.”78  The Act 
broadly defines an associated person to include “a person who performs services 
for or on behalf of [the entity],” a standard which is determined “by reference to 
all the relevant circumstances and not merely by reference to the nature of the 
relationship between [the person] and [the entity].”79  Consequently, all U.S.-
based and local personnel at a sponsor’s trial site in Africa potentially could be 
determined to be “affiliated persons,” and therefore the sponsor must ensure that 
its procedures are adequate to prevent all its potential affiliates from engaging in 
bribery prohibited under the Act. 
7. False Claims Act 
The federal False Claims Act (“FCA”) provides that any person who 
“knowingly presents, or causes to be presented, a false or fraudulent claim for 
payment or approval” will be “liable to the United States Government for a civil 
penalty of not less than $5,000 and not more than $10,000 [as adjusted for infla-
tion], plus three times the amount of damages which the Government sustains 
because of the act of that person.”80 
Academic institutions that receive funding from government agencies, such 
as NIH or CDC, to conduct research studies in Africa encounter several situations 
that could be characterized as having presented or having caused to be presented 
a false or fraudulent claim.  For example, institutional grantees can risk FCA 
liability if project investigators charge to a grant costs that do not relate to the 
 
 77. Bribery Act 2010, c. 23 § 7 (U.K.). 
 78. Id. 
 79. Id. at § 8. 
 80. 31 U.S.C. § 3729 (2012). 
  
2018] LAWS & ETHICS AFFECTING CLINICAL TRIALS IN AFRICA 259 
specific objects of the grant, or if required procurement processes are not fol-
lowed.  Additionally, for example, institutional grantees may face liability under 
the FCA for excessive time and effort charges on federally funded grants to sup-
port personnel salaries.81 
8. Registration on ClinicalTrials.gov 
The Food and Drug Administration Act of 1997 instructed the NIH to create 
a database listing clinical trials of drugs that treat “serious or life-threatening 
conditions.”82  In 2000, the NIH released the ClinicalTrials.gov website.83  The 
categories of clinical trials required to be registered on ClinicalTrials.gov were 
significantly expanded under the Food and Drug Administration Amendments 
Act of 2007 (“FDAAA”).84  The FDAAA requires that all clinical trials of drugs, 
biologics and devices be registered.85  Additionally, the FDAAA requires that 
summary results of registered trials of products approved, licensed or cleared by 
the FDA be posted on ClinicalTrials.gov.86  Under the FDAAA, the registration 
requirement applies to any trial that is an “applicable clinical trial,” defined as “a 
controlled clinical investigation, other than a phase I clinical investigation” of a 
drug subject to NDA registration or a biologics license application.87  Therefore, 
clinical trials conducted abroad must also be registered and listed on ClinicalTri-
als.gov if they are conducted as phase II or III trials in support of an NDA. 
In a new rulemaking, NIH clarified that some entirely ex-U.S. clinical trials 
are not subject to registration.  NIH issued a Notice of Proposed Rulemaking 
interpreting the provisions of the FDAAA on November 19, 2014 and issued a 
Final Rule on September 21, 2016.88  The Final Rule implements the FDAAA’s 
mandated expanded registry and results bank and also clarifies, in the preamble, 
that a clinical investigation of a drug, device or biological product that is being 
conducted entirely outside of the U.S. (i.e., a trial without any sites in the U.S. 
or in any territory of the U.S.) may or may not be an “applicable drug clinical 
 
 81. See, e.g., Yale University to Pay $7.6 Million to Resolve False Claims Act and Common Law 
Allegations, U.S. DEP’T OF JUSTICE (Dec. 23, 2008), https://oig.nasa.gov/press/pr2009-B.pdf. 
 82. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 113, 111 Stat. 
2295, 2311 (1997). 
 83. See U.S. NAT’L INST. OF HEALTH, History, Policies, and Laws, CLINICALTRIALS.GOV, 
https://clinicaltrials.gov/ct2/about-site/history (last updated July 2017) (providing a timeline of infor-
mation relating to the expansion of the ClinicalTrials.gov website). 
 84. See Food and Drug Administration Amendments Act of 2007 (FDAAA), Pub. L. No. 110-85, 
121 Stat. 904 (2007) (codified at 42 U.S.C. 282). 
 85. See id. 
 86. See id. 
 87. Id. 
 88. See Clinical Trials Registration and Results Submission, 79 Fed. Reg. 69,466 (Nov. 19, 2014); 
see also Clinical Trials Registration and Results Submission, 81 Fed. Reg. 64,982 (Sept. 21, 2016). 
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trial” (defined to include biologics) or an “applicable device clinical trial” re-
quired to be reported on ClinicalTrials.gov.89  Whether an exclusively ex-U.S. 
trial is an “applicable drug clinical trial” under the Final Rule is determined by 
whether the drug is subject to an NDA or to a biologics license application.90  If 
the drug or biological product is “manufactured outside of the United States or 
its territories, the clinical investigation sites are all outside of the United States, 
and the clinical investigation is not being conducted under an IND, [then] the 
drug or biological product would not be considered to be subject” to an NDA or 
to biologics license application, thus the clinical investigation would not be an 
“applicable drug clinical trial” requiring registration on ClinicalTrials.gov.91  
Likewise, if a clinical investigation for a device product is not conducted under 
an IDE and “is manufactured outside of the United States or its territories, and 
the clinical study sites are all outside of the United States and/or its territories” 
then the trial is not an applicable device clinical trial and is not subject to regis-
tration on ClinicalTrials.gov.92  The Final Rule clarifies for sponsors conducting 
exclusively ex-U.S. clinical trials for drugs not to be marketed within the U.S. 
that the related clinical trials are not required to be registered with the FDA. 
Biomedical journals provide another significant professional impetus for 
both academics and industry sponsors to register clinical trials on ClinicalTri-
als.gov.  The International Committee of Medical Journal Editors (“ICMJE”) re-
quires all journals seeking its approval to enforce the ICMJE policy requiring 
“registration of clinical trials in a public trials registry at or before the time of 
first patient enrollment as a condition of consideration for publication.”93  ICMJE 
specifically deems ClinicalTrials.gov to be an acceptable public trials registry, 
among others.94 
III. ETHICAL GUIDELINES FOR CLINICAL RESEARCH AND POTENTIAL ETHICAL 
ISSUES AFFECTING CLINICAL TRIALS IN AFRICA 
In countries where human subjects research law is meager, non-existent or 
weakly enforced, a series of ethical guidelines nevertheless provide standards for 
research involving human subjects.  Subsection A provides a brief overview of 
the history of the ethical principles applicable to clinical research in foreign 
countries.  Subsection B applies one set of ethical principles, the International 
Ethical Guidelines for Health-Related Research Involving Humans to certain 
 
 89. 81 Fed. Reg. 64,982, 65,013, 65,015. 
 90. See id. at 65,015. 
 91. Id. 
 92. Id. 
 93. Clinical Trial Registration, INT’L COMM. OF MED. J. EDITORS, Jan. 29, 2016, http://www.ic-
mje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. 
 94. See id. 
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ethical challenges likely to arise when clinical trials are conducted by sponsors 
and investigators in Africa. 
A. Sources of Ethical Principles 
After World War II, the Nuremberg Code (“the Code”) was drafted in re-
sponse to the medical experiments that Nazi doctors carried out on concentration 
camp prisoners.95  The Code lays out principles of ethical experimentation on 
human subjects.96  Officially, the Code was never adopted by the international 
community and, subsequently, questions emerged regarding “the applicability of 
its more stringent provisions when the research [was] clearly for the benefit of 
the patient.”97  Subsequent ethical guidelines have emerged to clarify and expand 
upon the Code.98 
One subsequent ethical guideline, the Declaration of Helsinki (the “Decla-
ration”), was promulgated by the World Medical Association in 1964 and is ad-
dressed primarily to physicians, although the Association encourages others in-
volved in medical research involving human subjects to adopt the Declaration’s 
principles.99  When a physician is involved in human subjects research, the Dec-
laration provides that it is “the duty of the physician to promote and safeguard 
the health, well-being and rights of patients, including those who are involved in 
medical research.”100 
In 1982, the Council for International Organizations of Medical Sciences 
(“CIOMS”) released the first version of its International Ethical Guidelines for 
Health-Related Research Involving Humans (the “Guidelines”).101  Most re-
cently updated in 2016, these Guidelines aim to “provide internationally vetted 
ethical principles and detailed commentary on how universal ethical principles 
should be applied, with particular attention to conducting research in low-re-
source settings.”102  The Guidelines provide that, “[t]o ensure that people in low-
 
 95. See Dawn Joyce Miller, Comment, Research and Accountability: The Need for Uniform Regula-
tion of International Pharmaceutical Drug Testing, 13 PACE INT’L L. REV. 198, 198–99 (2001) (stating 
that “the Nuremberg trials resulted in the first enunciation of ethical principles for medical research in-
volving human beings—the Nuremberg Code”). 
 96. See generally The Nuremburg Code, OFF. OF HIST. NAT’L INSTIT. OF HEALTH,  https://his-
tory.nih.gov/research/downloads/nuremberg.pdf (last visited Sept. 18, 2017) (setting forth several princi-
ples including voluntary consent of human subjects and avoidance of unnecessary physical or mental suf-
fering). 
 97. Miller, supra note 1, at 203.  
 98. See id. at 203 n.38, 205 (noting that the Declaration of Helsinki has expanded upon the Nurem-
burg Code’s protections). 
 99. See WORLD MED. ASS’N, supra note 48 at 199. 
 100. Id. 
 101. See Int’l Ethical Guidelines for Health-Related Research Involving Humans, COUNCIL FOR INT’L 
ORG. MED. SCI., https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf (last 
modified 2016). 
 102. Id. at viii. 
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resource settings receive equitable benefit from their participation in health-re-
lated research . . . local social value [must] be created.”103  Additionally, the 
Guidelines require that research in low-resource settings involve cooperation 
with government and other stakeholders “to make available as soon as possible 
any intervention or product developed, and knowledge generated . . . and to as-
sist in building local research capacity,” including for example “training labora-
tory personnel” and “educating the public about the nature of research and the 
benefits resulting from a particular study.”104 
The pharmaceutical trade organization PhRMA has published its Principles 
on Conduct of Clinical Trials, which is voluntary for its members to adopt.105  
These principles require IRB review, the informed consent of human research 
study participants, and mandate that sponsors of trials in the developing world 
seek to collaborate with relevant parties, such as local health authorities and host 
governments, in order “to address issues associated with the conduct of the pro-
posed study and its follow-up.”106 
B. Ethical Issues Affecting Clinical Trials in Africa 
The emergence of ethical guidelines for human subjects research in the 
post-World War II era indicates the perennial nature of difficult ethical questions 
that inevitably arise in working with human research subjects.  When research 
subjects are located in the developing world or emerging economies, applying 
the ethical guidelines often poses unique challenges.  This section applies the 
International Ethical Guidelines for Health-Related Research Involving Humans 
to some difficult paradigms that may emerge in conducting clinical trials in Af-
rica. 
1. Obtaining Adequate Informed Consent 
Assuring adequate informed consent poses serious challenges for sponsors 
and investigators in many African countries.  Investigators seeking informed 
consent may need to navigate barriers including language, comprehension, and 
local cultural norms.107  In some areas, “the use of local languages may facilitate 
the communication of information to potential participants” and allow the inves-
tigator to ensure the potential subjects’ comprehension.108  Investigators working 
in such circumstances must take into account the competence and neutrality of 
 
 103. Id. at 3. 
 104. Id. at 3, 5. 
 105. See PRINCIPLES ON CONDUCT OF CLINICAL TRIALS: COMMUNICATION OF CLINICAL TRIAL 
RESULTS, PHRMA 2 (rev. ed. 2014), http://phrma.org/sites/default/files/pdf/042009_clinical_trial_princi-
ples_final_0.pdf.  
 106. Id. at 11. 
 107. See COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 26, 34. 
 108. Id. at 35.  
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local translators to ensure that intended messages are being appropriately con-
veyed to research subjects. 
Additionally, investigators in the developing world may face challenges in 
ensuring that the prospective subject has adequately understood the information 
provided.  In countries with a low level of education among research subjects, 
investigators may have difficulty determining whether a person has understood 
the plan of research sufficient to give informed consent.109  Commentary in the 
Guidelines recommends that the investigator should give each potential research 
subject the “opportunity to ask questions” and provide the potential subject an-
swers before or during the research.110  Researchers also should use “evidence-
based methods for imparting information to ensure comprehension.”111 
Finally, investigators must respect the customs of a community while sim-
ultaneously ensuring that adequate individual consent is obtained.  For example, 
in some communities, the permission of a community leader, council of elders, 
or other designated authority may be expected before investigators approach in-
dividuals as potential human subjects.112  For example, it has been reported that 
the African Malaria Network Trust has obtained the permission of community 
leaders to conduct trials in the village of Balonghin, Burkina Faso; two sites in 
Mali; a site in Gabon; and various communities in the town of Bagamoyo, Tan-
zania.113  However, the Guidelines note that individual consent must still be ob-
tained, and a community leader’s consent cannot be used as a substitute.114 
The potential difficulties in obtaining adequate informed consent in certain 
circumstances are highlighted by the Pfizer clinical trial of Trovan in Nigeria.115  
In 1996, northern Nigeria experienced an epidemic of bacterial meningitis.116  
During the outbreak, Pfizer sponsored a study of an experimental anti-meningitis 
drug, Trovan, on a group of 200 pediatric subjects.117  Eleven children died in 
the trial, five of whom had taken Trovan and six of whom had taken another 
older antibiotic used for comparison.118  The study proved contentious on multi-
ple grounds, with a central issue being whether informed consent had been 
 
 109. See Meier, supra note 1, at 540. 
 110. COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 34. 
 111. Id. 
 112. See id. at 35. 
 113. See Aceme Nyika et al., Engaging Diverse Communities Participating in Clinical Trials: Case 
Examples from Across Africa, 9 MALARIA J. 1–11 (2010). 
 114. See COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 35. 
 115. See Donald G. McNeil, Jr., Nigerians Receive First Payments for Children Who Died in 1996 
Meningitis Trial, N.Y. TIMES (Aug. 11, 2011), available at http://www.ny-
times.com/2011/08/12/world/africa/12nigeria.html.  
 116. See id. 
 117. See id. 
 118. See id. 
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properly obtained from the children or their guardians.119  Plaintiffs in subse-
quent litigation alleged that the study had not appropriately implemented the 
treatment protocol requiring “researchers to offer or read the subjects documents 
requesting and facilitating their informed consent,” which researchers allegedly 
did not do “in either English or the subjects’ native language of Hausa.”120 
The Trovan clinical trial provides at least two lessons for investigators who 
seek to obtain informed consent when working in Africa.  First, ensuring that 
local subjects are sufficiently informed so as to be able to give adequate consent 
is likely to require coordination with local parties who can explain the potential 
risks and rewards of trial participation in linguistically appropriate and culturally 
competent language.121  Although this was apparently done in the Trovan study, 
records of the informed consent process were generally lacking.122  Second, 
therefore, it is best to create a record of the informed consent of research subjects 
or their guardians, if only to avoid future disputes and litigation.  When working 
with populations with high rates of illiteracy, written consent may be difficult to 
obtain, and alternative methods of documentation, such as audio or video record-
ings of statements of consent may be desirable, although investigators should 
also work with local partners to determine whether these technologies are likely 
to have a deterrent or coercive effect on potential subjects’ participation.123 
The HIVNET 012 Perinatal HIV Prevention Study, carried out in 1997 in 
Uganda, also illuminates the difficulties investigators face in obtaining adequate 
informed consent.124  At the time of the study, “the standard of care for prevent-
ing mother-to-child transmission in both the United States and Europe” consisted 
of a three-part maternal-infant zidovudine regimen.125  Due to a variety of fac-
tors, including “poor public health, clinical, and laboratory infrastructure and ca-
pacity [and] high rates of out-of-hospital delivery” the three-course regimen was 
 
 119. See Abdullahi v. Pfizer, Inc., 562 F.3d 163, 169–70 (2d. Cir. 2009). 
 120. Id. 
 121. See, e.g., Donald J. Krogstad, et al., Informed Consent in International Research: The Rationale 
for Different Approaches, 83 AM. J. TROPICAL MED. & HYGIENE 743, 746 (2010) (recommending that 
community leaders participate in the consent process, where appropriate, to ensure participants understand 
the risks and benefits). 
 122. See Joe Stephens, Panel Faults Pfizer in ‘96 Clinical Trial In Nigeria, WASH. POST, May 7, 2006, 
available at http://www.washingtonpost.com/wp-dyn/content/arti-
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 123. See Maria Kuthning & Ferdinand Hundt, Aspects of Vulnerable Patients and Informed Consent 
in Clinical Trials, 11 GER. MED. SCI. 1, 9 (2013); see also Niranjan G. Kulkarni, Audio-Video Recording 
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impractical in Uganda.126  The HIVNET 012 Study therefore tested a less inten-
sive regimen, consisting of a shorter course of antiretroviral drugs, for its efficacy 
in preventing mother-to-child HIV transmission.127 
In a report affirming the validity of the study’s questioned findings, the In-
stitute of Medicine (“IOM”) identified numerous ethical issues that the investi-
gators had faced in obtaining adequate informed consent.128  The report broadly 
noted that investigators “must tailor both the information and the way they con-
vey it to the needs of participants,” including “forms of documentation that are 
sensitive to local concerns,” noting in particular that “in some settings, [there 
may be] a fear of signing documents.”129  These cultural differences challenge 
investigators to adapt standard informed consent practices to local circum-
stances. 
One issue that the HIVNET 012 investigators confronted was whether a 
father’s informed consent should be obtained.130  The study’s consent forms in-
cluded a line for the father of the fetus or infant to sign if he was available.131  
The investigators counseled study participants to involve fathers in the decision-
making, but when participants “refused or were unable to involve fathers . . . the 
research team deemed those fathers ‘unavailable.’”132  In its review of the study, 
the IOM found that obtaining informed consent from fathers was not required by 
U.S. federal regulations, which only require a father’s consent when the research 
is solely of possible benefit and risk to the fetus, without any benefit or risk to 
the mother.133  In the HIVNET 012 study, however, both maternal and fetal 
health were involved, so the fathers’ consent was not required.134  Moreover, the 
IOM report noted that requiring the father to be involved in the study posed “con-
cerns about violating confidentiality by revealing the women’s HIV status to the 
fathers, especially given the stigmatization of HIV-positive individuals.”135  This 
study therefore provides an example of the moral and legal risks involved in im-
plementing an interventional drug study in a low-resource setting. 
2. Informed Consent Implications in Project Wind-Up and Wind-Down 
U.S. and E.U.-based staff can, without realizing, raise expectations for con-
tinued support, involvement or resources.  Cultural differences may give rise to 
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miscommunicated expectations such that research subjects may not realize that 
the foreign investigator and his or her foreign institution have not entered into a 
treatment relationship with them and that their actual relationship is different in 
character and duration from a treatment relationship.136  To satisfy the duty to 
obtain informed consent, investigators working in circumstances where the na-
ture of the research may be unclear have an ethical duty to ensure that they com-
municate to research subjects “how the research differs from routine medical 
care.”137  Critically, for subjects who are unfamiliar with controlled trials, ob-
taining adequate informed consent requires “an explanation of features of the 
research design, e.g. randomization [and] double blinding. . . .”138 
3. Avoiding Undue Inducement When Subjects Lack Medical Alternatives 
The comparative ease of recruiting study participants in African countries 
may, in some circumstances, raise concerns that a lack of medical treatment al-
ternatives creates an undue pressure on research subjects to participate in a clin-
ical trial.139  In particular, some have noted the possibility that, “[i]n the absence 
of health care, virtually any offer of medical assistance (even in the guise of re-
search) will be accepted as ‘better than nothing’ . . .”140  For example, in Africa, 
participation in clinical trials was highly valued in the past because it was, for 
many, the only means of accessing treatment for HIV/AIDS.141 
In clinical trials, health care that is essential to the safe conduct of the re-
search, as well as medical services unrelated to the study, may be provided to 
research subjects.  The Guidelines state that “[w]hen participants’ health needs 
during and after research cannot be met by the local health infrastructure or the 
participant’s pre-existing health insurance, the researcher and sponsor must make 
prior arrangements for adequate care for participants with local health authori-
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ties, members of the communities from which persons are drawn, or nongovern-
mental organizations such as health advocacy groups.”142  Additionally, the 
Guidelines note that addressing participants’ health needs requires researchers 
and sponsors to “make plans for . . . how care will be provided during the re-
search when researchers discover conditions other than those under study.”143 
For clinical trials conducted in resource-poor settings in Africa, investiga-
tors must be aware of how the availability of health care services may affect the 
choices of research subjects.144  The Guidelines note that providing medical ser-
vices as a component of a clinical trial has the potential to run afoul of an ethical 
duty to avoid compensation so large that it creates an undue pressure to consent 
against the subject’s better judgment.145  However, the Guidelines do not prohibit 
all research when there is merely a possibility that subjects will be induced to 
participate in a trial because it offers benefits relative to the routinely available 
medical care.146  Noting that “the compensation that makes some people volun-
teer against their better judgment depends on their personal situation,” the Guide-
lines provide that “[r]esearch ethics committees must evaluate monetary and 
other forms of compensation in light of the traditions and socio-economic con-
text of the particular culture and population in order to determine whether the 
average participant expected to enrol[l] in the study is likely to participate in the 
research against his or her better judgment because of the compensation of-
fered.”147  Therefore, in order to provide ethically sound financial and medical 
benefits to clinical trial participants in resource-poor settings in Africa, sponsors 
and investigators must take into account the potential for undue inducement, 
when the participants’ access to alternative sources of medical care is limited. 
4. Ethical Issues in Identifying Human Subjects 
When working in African countries, certain ethical challenges emerge re-
lated to the identification of research subjects.  One set of challenges relates to 
the equity of the decision to locate such research in the country with populations 
and communities with limited resources.148  An additional set of challenges 
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emerges when selecting research subjects from among the population of the de-
veloping country. 
When working in populations with limited resources, the Guidelines require 
that the sponsor and investigator must make every effort to ensure that “the re-
search is responsive to the health needs or priorities” of the population or com-
munity and that “any intervention or product developed, and knowledge gener-
ated” will be made available “for the population or community in which the 
research is carried out.”149  First, responsiveness requires more than a determi-
nation that a studied disease is prevalent in the population, and includes further 
analysis into whether successful interventions are to be made available to the 
population, especially if the population may be unable to afford even a new drug 
that is cheaper than the standard treatment in other countries.150  Second, “[p]ost-
trial access plans are of particular concern” as a means of ensuring availability 
of products developed in “low-resource settings where governments lack the 
means or infrastructure to make such products widely available.”151  However, 
the Guidelines also provide that issues of post-trial availability in populations 
and communities should not be construed to preclude studies evaluating novel 
concepts, for example, in cases seeking to evaluate the efficacy of an experi-
mental drug in treating a disease that occurs only in low-resource settings and 
“such research could not be carried out reasonably well in more developed com-
munities.”152  In such instances, although there would not be a specific product 
that could be made available to the population or community at the end of the 
experimental trial even if the concept is found to be valid, the research may be 
ethically justifiable as “subsequent phases of research could result in a product 
that would be made reasonably available.”153 
Once a sponsor or sponsor-investigator determines that a clinical trial site 
will be located within a particular country, another set of ethical considerations 
apply to the selection of individual research subjects from among the popula-
tion.154  Ethical guidelines mandate that “[g]roups that are unlikely to benefit 
from any knowledge gained from the research should not bear a disproportionate 
share of the risks and burdens of research participation” and “[g]roups that are 
under-represented in medical research should be provided appropriate access to 
participate.”155  Interpreting this provision, the Guidelines’ commentary provides 
that, “[w]hen burdens or benefits of research are to be apportioned unequally 
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among individuals or groups, the criteria for unequal distribution should be sci-
entifically and ethically justified rather than arbitrarily or conveniently cho-
sen.”156  To satisfy these ethical obligations, sponsors and investigators should 
be cognizant in their selection of particular ethnic or social groups within the 
country for possible study recruitment.  Additionally, if there will be waiting lists 
for clinical trial enrollment, it is essential that any prioritization status to certain 
subjects be ethically justifiable.  For example, a sound scientific reason may jus-
tify prioritizing subjects with particularly acute conditions, if relevant to the re-
search being conducted.  However, other potential criteria for participation, such 
as family relation to local clinical staff, should be avoided as not scientifically 
justifiable. 
IV. CONCLUSION 
Clinical trials conducted in Africa offer numerous potential benefits for 
studying diseases impacting public health, for pharmaceutical companies seek-
ing to test the efficacy of new drugs, for local investigators seeking academic 
opportunities, and for local populations that may have lacked historical access to 
clinical trials or even to basic medical care.  Conducting clinical trials in Africa, 
however, poses unique legal considerations that emerge from the complex frame-
work of foreign and U.S. laws that may apply to foreign clinical trial sites.  Ad-
ditionally, clinical trials in Africa can present a number of ethically challenging 
situations with which sponsors and investigators may be unfamiliar.  In navi-
gating challenges such as obtaining informed consent in unfamiliar cultural and 
linguistic conditions, sponsors and investigators will find that the most essential 
ingredient to a successful research or service project in a developing country is 
having a competent and trustworthy local partner institution or set of investiga-
tors.  Identifying such entities and persons contributes significantly to ethical and 
scientifically rigorous research in such projects. 
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